While further follow-up is needed to determine the durability of response, brexucabtagene autoleucel represents a highly active treatment option for relapsed MCL, particularly among patients with progression following BTKi treatment and patients with high-risk features including blastoid morphology and TP53 mutation. The gene discussed is TP53; the disease is mantle cell lymphoma.